JP2025512831A5 - - Google Patents

Info

Publication number
JP2025512831A5
JP2025512831A5 JP2024557204A JP2024557204A JP2025512831A5 JP 2025512831 A5 JP2025512831 A5 JP 2025512831A5 JP 2024557204 A JP2024557204 A JP 2024557204A JP 2024557204 A JP2024557204 A JP 2024557204A JP 2025512831 A5 JP2025512831 A5 JP 2025512831A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
dmt
meo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512831A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/057870 external-priority patent/WO2023186823A1/en
Publication of JP2025512831A publication Critical patent/JP2025512831A/ja
Publication of JP2025512831A5 publication Critical patent/JP2025512831A5/ja
Pending legal-status Critical Current

Links

JP2024557204A 2022-03-27 2023-03-27 認知機能障害の治療 Pending JP2025512831A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP22000083 2022-03-27
EP22000086.3 2022-03-27
EP22000083.0 2022-03-27
EP22000086 2022-03-27
EP23153995 2023-01-30
EP23153939.6 2023-01-30
EP23153995.8 2023-01-30
EP23153939 2023-01-30
PCT/EP2023/057870 WO2023186823A1 (en) 2022-03-27 2023-03-27 Treatment of cognitive dysfunction

Publications (2)

Publication Number Publication Date
JP2025512831A JP2025512831A (ja) 2025-04-22
JP2025512831A5 true JP2025512831A5 (enExample) 2026-04-10

Family

ID=86007166

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2024557755A Pending JP2025511081A (ja) 2022-03-27 2023-03-27 睡眠障害の治療における使用のための5-MeO-DMT
JP2024557191A Pending JP2025510912A (ja) 2022-03-27 2023-03-27 双極性障害を処置するための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557759A Pending JP2025510369A (ja) 2022-03-27 2023-03-27 社会的/情動的引きこもりまたは離隔の処置のための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557205A Pending JP2025510916A (ja) 2022-03-27 2023-03-27 精神運動遅滞の治療のための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557758A Pending JP2025510368A (ja) 2022-03-27 2023-03-27 不安の処置
JP2024557204A Pending JP2025512831A (ja) 2022-03-27 2023-03-27 認知機能障害の治療

Family Applications Before (5)

Application Number Title Priority Date Filing Date
JP2024557755A Pending JP2025511081A (ja) 2022-03-27 2023-03-27 睡眠障害の治療における使用のための5-MeO-DMT
JP2024557191A Pending JP2025510912A (ja) 2022-03-27 2023-03-27 双極性障害を処置するための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557759A Pending JP2025510369A (ja) 2022-03-27 2023-03-27 社会的/情動的引きこもりまたは離隔の処置のための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557205A Pending JP2025510916A (ja) 2022-03-27 2023-03-27 精神運動遅滞の治療のための5-メトキシ-n,n-ジメチルトリプタミン
JP2024557758A Pending JP2025510368A (ja) 2022-03-27 2023-03-27 不安の処置

Country Status (9)

Country Link
US (9) US20250205199A1 (enExample)
EP (7) EP4499076A1 (enExample)
JP (6) JP2025511081A (enExample)
KR (6) KR20250005181A (enExample)
CN (2) CN119053327A (enExample)
AU (6) AU2023246545A1 (enExample)
CA (6) CA3255505A1 (enExample)
IL (6) IL315898A (enExample)
WO (9) WO2023186797A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
WO2022153266A1 (en) 2021-01-15 2022-07-21 Beckley Psytech Limited Ergoline analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202306256D0 (en) * 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2026078143A1 (en) 2024-10-09 2026-04-16 GH Research Ireland Limited Combinations of 5-meo-dmt with antidepressants for treating depression

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20040234699A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
ATE489981T1 (de) 2006-08-01 2010-12-15 Stobi Gmbh & Co Kg Ventilballon für inhalatoren
EP3713568A1 (en) * 2017-10-26 2020-09-30 Consejo Superior de Investigaciones Cientificas (CSIC) Combination product for the treatment of neurological and/or psychiatric disorders
AU2020225766B2 (en) * 2019-02-22 2025-10-30 GH Research Ireland Limited Compositions comprising 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for use in treating mental disorders
EA202192318A1 (ru) 2019-02-22 2021-12-21 Гх Рисерч Айрленд Лимитед 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии
JP2022529781A (ja) * 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
EP3868364A1 (en) * 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
WO2021216489A1 (en) * 2020-04-20 2021-10-28 Lobe Sciences Ltd. Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury
KR20230024378A (ko) * 2020-06-12 2023-02-20 벡클리 싸이테크 리미티드 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물
US11406619B2 (en) * 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt

Similar Documents

Publication Publication Date Title
JP2025510296A5 (enExample)
JP2025510369A5 (enExample)
JP2025510368A5 (enExample)
JP2025511081A5 (enExample)
JP2025510295A5 (enExample)
ES2907325T3 (es) Tratamiento de síndrome del cromosoma X frágil y autismo con cannabidiol
JP2025510916A5 (enExample)
JP2025511084A5 (enExample)
JP2025510912A5 (enExample)
JP2025510913A5 (enExample)
JP2025510294A5 (enExample)
BR112020005998A2 (pt) uso de formulação de fenfluramina na redução em número e em frequências de crises convulsivas em populações de pacientes
JP2022524008A5 (enExample)
Francis Long-term beclomethasone dipropionate aerosol therapy in juvenile asthma.
JP2025510912A (ja) 双極性障害を処置するための5-メトキシ-n,n-ジメチルトリプタミン
CN107823195A (zh) R‑氯胺酮在抑郁症急性期治疗中的应用
AU2021281118A1 (en) Treatment of autism spectrum disorder with cannabidiol
Ziskind et al. Can schizophrenia change to affective psychosis?
EA029650B1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
EP3701956B1 (en) Prophylactic and/or therapeutic agent for dementia
WO2024078507A1 (zh) 麦角甾醇在制备防治胃溃疡药物中的应用
Egbu et al. Steroid-induced hiccups in a patient managed for pseudo foster-kennedy syndrome: a case report of good outcome with the use of gabapentin
RU2819818C1 (ru) Способ ускоренного снижения патологического влечения к курению табака в условиях онкологического стационара у мужчин
Braun Reserpine as a therapeutic agent in schizophrenia
RU2468813C1 (ru) Средство для профилактики или лечения острых и хронических нарушений мозгового кровообращения, применение и способ лечения